# A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

> **NCT02576548** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 47 (actual)

## Conditions studied

- HER2 Expressing Breast or Gastric/Stomach Cancers

## Interventions

- **BIOLOGICAL:** MEDI4276

## Key facts

- **NCT ID:** NCT02576548
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-23
- **Primary completion:** 2018-05-23
- **Final completion:** 2018-05-23
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576548, "A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02576548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*